公开(公告)号：US20090016963A1

公开(公告)日：2009-01-15

申请号：US10576051

申请日：2004-10-21

申请人： Dalia Cohen ,  Uwe Jochen Dengler ,  Danny Garza ,  Anju N. Kelkar ,  Mary Konsolaki ,  Ho-Juhn Song

发明人： Dalia Cohen ,  Uwe Jochen Dengler ,  Danny Garza ,  Anju N. Kelkar ,  Mary Konsolaki ,  Ho-Juhn Song

IPC分类号： A61K39/395 ,  A61K31/7088 ,  C12Q1/68 ,  G01N33/68 ,  A61K49/00 ,  A61K48/00 ,  A61P25/28

CPC分类号： C12Q1/6883 ,  C12Q1/6837 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate neurodegenerative conditions. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat neurodegenerative conditions.

摘要翻译： 本发明公开了用于开发治疗，预防或改善神经变性病症的新治疗剂的合适的基因和多肽靶标。 本发明还涉及治疗，预防或改善所述病症及其药物组合物的方法，以及鉴定具有治疗神经变性疾病的治疗有效性的化合物的方法。

公开(公告)号：US06900367B2

公开(公告)日：2005-05-31

申请号：US09964899

申请日：2001-09-27

申请人： Dalia Cohen ,  Uwe Jochen Dengler ,  Alyce Lynn Finelli ,  Felix Freuler ,  Mary Konsolaki ,  Mischa Werner Henri Marie Reinhardt ,  Susan Zusman

发明人： Dalia Cohen ,  Uwe Jochen Dengler ,  Alyce Lynn Finelli ,  Felix Freuler ,  Mary Konsolaki ,  Mischa Werner Henri Marie Reinhardt ,  Susan Zusman

IPC分类号： A01K67/027 ,  A01K67/033 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P25/28 ,  A61P43/00 ,  C07K14/47 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  A01K67/00 ,  G01N33/00

CPC分类号： C07K14/4711 ,  A01K67/0339 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505

摘要： Transgenic flies displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.

摘要翻译： 公开了由于人APP基因的Abeta和C99部分的表达而显示改变的表型的转基因苍蝇。 还公开了这些苍蝇在鉴定果蝇基因和潜在参与阿尔茨海默病的这些果蝇基因的人类同源物的方法中的使用。 还公开了使用所述人类同系物作为用于开发用于治疗阿尔茨海默病和与APP途径中的缺陷相关的其它病症的治疗剂的药物靶标，以及包含针对这些基因的物质的药物组合物。

公开(公告)号：US20050138676A1

公开(公告)日：2005-06-23

申请号：US10975523

申请日：2004-10-28

申请人： Dalia Cohen ,  Uwe Dengler ,  Alyce Finelli ,  Felix Freuler ,  Mary Konsolaki ,  Mischa Reinhardt ,  Susan Zusman

发明人： Dalia Cohen ,  Uwe Dengler ,  Alyce Finelli ,  Felix Freuler ,  Mary Konsolaki ,  Mischa Reinhardt ,  Susan Zusman

IPC分类号： A01K67/027 ,  A01K67/033 ,  A61K38/00 ,  A61K45/00 ,  A61K48/00 ,  A61P25/28 ,  A61P43/00 ,  C07K14/47 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566

CPC分类号： C07K14/4711 ,  A01K67/0339 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505

摘要： Transgenic flies displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.

摘要翻译： 公开了由于人APP基因的Abeta和C 99部分的表达而显示改变的表型的转基因苍蝇。 还公开了这些苍蝇在鉴定果蝇基因和潜在参与阿尔茨海默病的这些果蝇基因的人类同源物的方法中的使用。 还公开了使用所述人类同系物作为用于开发用于治疗阿尔茨海默病和与APP途径中的缺陷相关的其它病症的治疗剂的药物靶标，以及包含针对这些基因的物质的药物组合物。

公开(公告)号：US20060040884A1

公开(公告)日：2006-02-23

申请号：US11191875

申请日：2005-07-28

申请人： Francis Buxton ,  Dalia Cohen ,  Denise Fischer ,  Shaowen Wang

发明人： Francis Buxton ,  Dalia Cohen ,  Denise Fischer ,  Shaowen Wang

IPC分类号： A61K48/00 ,  C07H21/04

CPC分类号： C12N15/1137 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12Y203/01048 ,  G01N2333/91057 ,  C12N2310/3525

摘要： Antisense compounds, compositions and methods are provided for modulating the expression of trapoxin A regulated genes, including but not limited to those genes induced by ectopic expression of p21waf1 that are disclosed herein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding these genes. Methods of using these compounds for modulation of expression of these genes and for treatment of diseases associated with these genes, as well as those associated with abnormal HDAC activity, particularly cancer or others characterized by abnormal cell proliferation, are provided. Furthermore, the invention relates to the use of RhoB as a biomarker to evaluate the efficacy of treatment of humans with abnormal HDAC activity including proliferative diseases such as cancer. Also disclosed is a method for identifying HDAC inhibitors and trapoxin analogs based on the surprising discovery that up regulation or RhoB and increased RhoB protein levels are associated with HDAC inhibition.

摘要翻译： 提供反义化合物，组合物和方法用于调节调节蛋白A调节的基因的表达，包括但不限于本文公开的由p21 的异位表达诱导的那些基因。 组合物包含靶向编码这些基因的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节这些基因的表达和治疗与这些基因有关的疾病的方法，以及与异常HDAC活性相关的疾病，特别是癌症或以异常细胞增殖为特征的其他方法。 此外，本发明涉及RhoB作为生物标志物的用途，以评估治疗具有异常HDAC活性的人的功效，包括增殖性疾病如癌症。 还公开了基于令人惊讶的发现，鉴定HDAC抑制剂和诱导蛋白类似物的方法，即上调或RhoB和增加的RhoB蛋白水平与HDAC抑制相关。

公开(公告)号：US20070134744A1

公开(公告)日：2007-06-14

申请号：US11650375

申请日：2007-01-05

申请人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

发明人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

IPC分类号： G01N33/574 ,  C12N5/08 ,  A61K31/427

CPC分类号： G01N33/5011 ,  A61K47/6803 ,  A61K47/6851 ,  C12N5/0693 ,  C12N2503/02 ,  G01N33/5008 ,  G01N33/5014

摘要： Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothilone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invention also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.

摘要翻译： 披露埃坡霉素抗性细胞系。 本发明还公开了鉴定对埃坡霉素抗性细胞具有细胞毒性或是埃坡霉素的化学敏化剂或类似物的物质的方法。 本发明还公开了用于鉴定埃坡霉素抗性细胞并用于在体外和体内抑制埃坡霉素抗性细胞生长的方法。 本发明还公开了对埃坡霉素抗性细胞特异的抗体。 还公开了使用公开的埃坡霉素抗性细胞系鉴定微管稳定剂的方法。

公开(公告)号：US20070082339A1

公开(公告)日：2007-04-12

申请号：US11246802

申请日：2005-10-07

申请人： Dalia Cohen ,  Shaowen Wang

发明人： Dalia Cohen ,  Shaowen Wang

IPC分类号： C12Q1/68 ,  G01N33/567

CPC分类号： C12Q1/48 ,  C12Q1/6876 ,  C12Q2600/158

摘要： The invention relates to the use of gene and protein expression levels as a marker for HDAC inhibition. Also disclosed are in vivo and in vitro methods for screening a compound for HDAC inhibitory activity, as well as methods for monitoring the therapeutic efficacy of an HDAC inhibitor in a subject in vivo and for determining resistance to an HDAC inhibitor in vitro or in vivo.

摘要翻译： 本发明涉及使用基因和蛋白质表达水平作为HDAC抑制的标志物。 还公开了用于筛选化合物用于HDAC抑制活性的体内和体外方法，以及用于监测体内受试者体内HDAC抑制剂的治疗功效以及用于在体外或体内测定对HDAC抑制剂的抗性的方法。

公开(公告)号：US20060135412A1

公开(公告)日：2006-06-22

申请号：US10535385

申请日：2003-11-21

申请人： Dalia Cohen ,  Larry Gaither

发明人： Dalia Cohen ,  Larry Gaither

IPC分类号： A61K38/17 ,  A61K38/12 ,  A61K48/00

CPC分类号： G01N33/502 ,  A61K38/12 ,  A61K38/1709 ,  C07K14/4711 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/5023 ,  G01N33/6896 ,  G01N2500/04 ,  G01N2800/2814 ,  G01N2800/2835

摘要： The invention discloses previously unknown modifiers of Aβ secretion. These proteins are identified as suitable targets for the development of new therapeutics to treat, prevent or ameliorate pathological conditions associated with Aβ secretion, including Alzheimer's Disease. The invention also relates to methods to treat, prevent or ameliorate said pathological conditions and pharmaceutical compositions therefore comprising modulators with inhibitory effects on the activity and/or expression of these modifiers.

摘要翻译： 本发明公开了以前未知的Abeta分泌调节剂。 这些蛋白质被鉴定为用于开发新治疗剂以治疗，预防或改善与Aβ分泌相关的病理状况（包括阿尔茨海默病）的合适靶标。 本发明还涉及治疗，预防或改善所述病理状况和药物组合物的方法，因此包括对这些改性剂的活性和/或表达具有抑制作用的调节剂。